Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) has joined a Canadian oncology research consortium as a co-applicant in a competitive Terry Fox Research Institute grant, the company announced. The grant supports the development of Onco-Innovations' SynoGraph(TM) artificial intelligence platform, which aims to enhance the prediction of how investigational therapies may perform in human trials.
The research project will investigate whether causal AI, combined with preclinical research and real-world clinical, genomic, and imaging data, can improve predictions of therapeutic outcomes. Redwood AI will contribute proprietary data integration, feature engineering, and physicochemical modelling methods. The company will work alongside Onco-Innovations and academic research partners that will supply clinical and genomic datasets. This collaboration expands Redwood AI's applications in life sciences and highlights the potential of combining AI with chemical modelling to support drug development.
For investors, the partnership signals a strategic move into the life sciences sector, which could diversify Redwood AI's revenue streams and enhance its technological portfolio. The company is already known for developing advanced artificial intelligence and cybersecurity solutions for defense, public safety, and life sciences. Its technology is designed to help organizations prepare for quantum-enabled cybersecurity threats while enabling faster, more efficient development of new therapies and chemistry-driven applications. The latest news and updates relating to RDWCF are available in the company's newsroom at https://ibn.fm/RDWCF.
The announcement was disseminated on behalf of Redwood AI Corp. and may include paid advertising. To view the full article, visit https://ibn.fm/aMe02. The news was distributed through AINewsWire, a specialized communications platform focused on the latest advancements in artificial intelligence, including the technologies, trends, and trailblazers driving innovation forward.
AINewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
The collaboration with the Terry Fox Research Institute grant recipients could accelerate the development of AI-driven tools for oncology, potentially leading to more efficient drug development processes and better patient outcomes. It also underscores the growing role of artificial intelligence in healthcare and the increasing interest from technology companies in applying their expertise to life sciences challenges.
